Showing 1301-1310 of 1484 results for "".
- Dermira's Novel Facial Acne Treatment Passes Muster in Phase 2b Studyhttps://practicaldermatology.com/news/dermiras-drm01-performs-well-in-facial-acne-study/2458571/Dermira’s novel topical sebum inhibitor -- DRMO1 -- may put the brakes on facial acne, according to topline results from a Phase 2b dose-ranging study that is paving the way toward a Phase 3 Clinical Program. DRM01 is a novel, small molecul
- Use of Personal Care Products During Pregnancy Linked to Adverse Effects in Newbornshttps://practicaldermatology.com/news/use-of-personal-care-products-during-pregnancy-linked-to-adverse-effects-in-newborns/2458575/Personal care products used during pregnancy may be linked to adverse reproductive effects in newborns, report researchers from SUNY Downstate Medical Center’s School of Public Health. The long-term consequences of this are not clear and the findings must be reproduced in larg
- Skin Cancer Expert Perry Robins, MD Joins Emerald's Advisory Boardhttps://practicaldermatology.com/news/skin-cancer-expert-perry-robins-md-joins-emeralds-advisory-board/2458574/New York City dermatologist Perry Robins, MD has joined Emerald Medical Applications Corp.’s advisory board. Emerald, an Israeli-based company, is developing DermaCompare™, a proprietary artificial intelligence free app 
- Mission Pharmacal's Lycelle Head Lice Removal Kit Now Available In Pharmacieshttps://practicaldermatology.com/news/mission-pharmacals-lycelle-head-lice-removal-kit-now-available-in-pharmacies/2458578/Mission Pharmacal's former prescription Lycelle Head Lice Removal Kit will now be available without a prescription. Lycelle is a treatment for the elimination of head lice and their eggs. Lycelle uses a non-pesticidal formulation that is safe for use with children as young as two years o
- Lilly's Taltz Now Available for Psoriasishttps://practicaldermatology.com/news/lillys-taltz-now-available-for-psoriasis/2458581/Eli Lilly and Company's Taltz (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis is now available by prescription order through a contracted network of specialty pharmacies in the United States. Lilly is also offering patient support programs to help ensu
- Largest Independent US Psoriasis Registry to Track Safety of Ixekizumab Biologic Treatmenthttps://practicaldermatology.com/news/largest-independent-us-psoriasis-registry-to-track-safety-of-ixekizumab-biologic-treatment/2458583/The Corrona Psoriasis Registry will track the drug safety reporting for ixekizumab, Eli Lilly and Company's biologic medication that was recently approved for the treatment of moderate-to-severe plaque psoriasis. The registry is a joint collaboration between the National Psoriasis Foundation
- Study IDs Rosacea-Alzheimers Linkhttps://practicaldermatology.com/news/study-ids-rosacea-alzheimers-link/2458584/Rosacea may be linked to an increased risk of dementia—in particular Alzheimer’s disease, new research suggests. This risk was highest in older patients and in patients where rosacea was diagnosed by a hospital dermatologist. The new findings are published in the </
- Modernizing Medicine's Dermatology-specific EHR System Top Rated by KLAShttps://practicaldermatology.com/news/modernizing-medicines-dermatology-specific-ehr-system-top-rated-by-klas/2458591/Modernizing Medicine, Inc.’s EMA Dermatology has been rated the top electronic health record (EHR) system for dermatologists in the inaugural KLAS “Ambulatory Specialty 2016 One Size Does Not Fit All Performance Report.” KLAS, best known for its “Best in KLAS: Soft
- Valeant Names Joseph C. Papa as Chairman and CEOhttps://practicaldermatology.com/news/valeant-names-joseph-c-papa-as-chairman-and-ceo/2458593/Valeant Pharmaceuticals International, Inc's Board of Directors has named Joseph C. Papa to become its Chairman and Chief Executive Officer. Mr. Papa is expected to join Valeant by early May. He will join Valeant from Perrigo Company plc, a leading global health
- Oculus Innovative Sciences' Microcyn®-based Lasercyn™ Gel Cleared for Post-procedure Usehttps://practicaldermatology.com/news/oculus-innovative-sciences-microcyn-based-lasercyn-gel-cleared-for-post-procedure-use/2458597/Oculus Innovative Sciences, Inc. has received a new 510(k) clearance from the FDA for the company's new Microcyn®-based Lasercyn™ Gel. Under the supervision of a healthcare professional, Lasercyn Gel is int